GlassScriptPhysician profile
Taylor J Huinker
NPI 1851881213
$2,644.11
in general payments reported to CMS, 2019-2025
25 companies · $844 in 2025
The $844 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $398 · 2023: $486 · 2024: $811 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105 · Education: $35.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.03 |
| Education | $35.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $539.61 | 2022-2025 | Entyvio, Gattex |
| Abbvie INC. | $326.34 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $314.23 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $297.30 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Celltrion USA INC. | $215.84 | 2024-2025 | Vegzelma, Zymfentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.58 | 2021-2022 | |
| Organon LLC | $98.33 | 2023-2025 | Hadlima, Renflexis |
| Genzyme Corporation | $87.32 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $77.88 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $68.48 | 2025 | Iqirvo |
| Ardelyx, INC. | $65.40 | 2022-2023 | Ibsrela |
| Fresenius Kabi USA, LLC | $63.13 | 2023-2025 | Idacio |
| Merck Sharp & Dohme LLC | $49.86 | 2022-2023 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.69 | 2023 | Cyltezo |
| Vertex Pharmaceuticals Incorporated | $42.82 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $42.66 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $31.47 | 2023 | Ocaliva |
| Amgen INC. | $23.67 | 2023 | Amjevita |
| Nestle Healthcare Nutrition INC. | $23.31 | 2022 | |
| Exact Sciences Corporation | $18.35 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $18.03 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $16.36 | 2022 | |
| Lilly USA, LLC | $16.07 | 2025 | Omvoh |
| Gilead Sciences, INC. | $14.73 | 2025 | |
| Saluda Medical Americas, INC. | $14.65 | 2025 | Evoke |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Huinker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.